Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Sensor Based Vital Signs Monitoring of Covid 19 Patients During Home Isolation (HSC19)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04335097
Recruitment Status : Recruiting
First Posted : April 6, 2020
Last Update Posted : May 13, 2020
Sponsor:
Collaborators:
University of Stavanger
Oslo University Hospital
Norwegian Telemedicine
University of Basque Country (UPV/EHU)
Information provided by (Responsible Party):
Lars Wik, Ullevaal University Hospital

Tracking Information
First Submitted Date  ICMJE April 1, 2020
First Posted Date  ICMJE April 6, 2020
Last Update Posted Date May 13, 2020
Actual Study Start Date  ICMJE April 22, 2020
Estimated Primary Completion Date April 8, 2021   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: April 2, 2020)
  • Stop home isolation [ Time Frame: 1 to 21 days ]
    Day during home isolation it was stopped due to hospitalization
  • NEWS score [ Time Frame: 1 to 21 days ]
    5 or >3 for one organ system
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: April 2, 2020)
  • Clinic at hospitalization [ Time Frame: At admittance hospital ]
    Relevant vital clinical findings
  • Symptoms developed [ Time Frame: Duration of home isolation ]
    Symptoms developed during home isolation
  • Relative/peers evaluation of the patient [ Time Frame: Duration of home isolation ]
    Their description of vital sign development
  • Serious of symptoms at admittance hospital [ Time Frame: Hospital stay ]
    Referred to ICU, intubated, length of stay
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Sensor Based Vital Signs Monitoring of Covid 19 Patients During Home Isolation
Official Title  ICMJE Sensor Based Vital Signs Monitoring of Patients With Clinical Manifestation of Covid 19 Disease During Home Isolation, a Randomized Feasibility Study
Brief Summary

Severe acute respiratory syndrome (SARS) SARS-Cov-2 disease (COVID-19) is an infectious disease caused by a coronavirus. The pandemic first described in Wuhan, China, has since spread across the whole world and caused dramatic strain on health care in many countries. Patients infected with the virus mostly report mild to moderate respiratory symptoms like shortness of breath and coughing, and febrile symptoms. It is of paramount importance to preserve health service capacity by identifying those with serious illness without transferring all infected patients to emergency rooms or Hospitals. In addition, it is important to identify seriously ill patients early enough and before they reach a point of deterioration where they can be extremely challenging to handle in both prehospital and hospital environment.

The present study is designed to sample biosensor data from patients treated and observed at home due to mild and moderate SARS-Cov-2 disease. Such a system would be useful, both for the treatment of individual patients as well as for assessing the efficacy and safety of care given to these patients. Investigators intend to improve quality and safety of home care by continuous monitoring and a set of rules for follow-up.

Investigators hypothesized that patients and local health system may benefit from the feedback of a simple monitoring system, which detects changes in respiration, temperature and circulation variables in combination with the patient's subjective experiences of care. Patients may be referred to hospitalization earlier. In the present study we will use live continuous and non-continuous biosensor data to monitor the development of vital parameters for Covid 19 patients compared with patients who are not monitored electronically (standard of care).

Detailed Description

Severe acute respiratory syndrome (SARS) SARS-Cov-2 disease (COVID-19) is an infectious disease caused by a coronavirus. The pandemic first described in Wuhan, China, has since spread across the whole world and caused dramatic strain on health care in many countries. The virus spreads primarily through droplets of saliva or discharge from the nose when an infected person coughs or sneezes.1 Patients infected with the virus mostly report mild to moderate respiratory symptoms like shortness of breath and coughing, and febrile symptoms. Most recover without requiring special treatment. However, older people, and those with underlying medical problems (cardiovascular disease, diabetes, chronic respiratory disease, and cancer) are more likely to develop serious illness.1 Younger patients have been reported with serious illness as well. In the present situation, it is of paramount importance to preserve health service capacity by identifying those with serious illness without transferring all infected patients to emergency rooms or Hospitals. In addition, it is important to identify seriously ill patients early enough and before they reach a point of deterioration where they can be extremely challenging to handle in both prehospital and hospital environment.

The number of subjects with positive test of the virus is increasing and so does the number of patients hospitalized.2 In parallel, most patients with positive test result or typical clinical symptoms are at home with information what to do if their clinical symptom status deteriorates.2 The Norwegian Interaction Reform was implemented in 2012.3 Key elements of the reform are guidance of the health care in the future and identify new directions. Prevention and early efforts are important and this will be achieved by creating co-working arenas for different parts of our health system. More health services must be moved closer to where the inhabitants live and simultaneously strengthening the community health system. New tools for monitoring the well-being of the patients must be developed in order to act early enough to avoid severe deterioration of health status and avoid new hospitalization. This goal has become even more important during the Covid 19 pandemic because the healthcare system is not prepared or built to take care of all these patients in hospitals.

In the local community's wearable and wireless biosensors collecting continuous physiological data (CPD) in real time in order to generate information reflecting the patients' current state is established. This is recognized as welfare technology, and it is a generic term for a heterogeneous group of technologies.4 There are few studies documenting their efficacy, effectiveness and efficiency. One key driver for the development of wearable biosensors is the potential to use CPD to generate real-time, clinically actionable insights from predictive analytics that include early warnings of clinical deterioration and prompts for behavioral changes. The advent of machine learning methods that can detect subtle patterns from large sets of CPD may make this achievable.

Using CPD to guide clinical decisions may be a major advance for patients with chronic diseases and at present time when our health system is put on an extreme stretch. This may drive the evolution from episodic to continuous patient care.

The present study is designed to sample biosensor data from patients treated and observed at home due to mild and moderate SARS-Cov-2 disease. Such a system would be useful, both for the treatment of individual patients as well as for assessing the efficacy and safety of care given to these patients. Investigators intend to improve quality and safety of home care by continuous monitoring and a set of rules for follow-up.

Investigators hypothesized that patients and local health system may benefit from the feedback of a simple monitoring system, which detects changes in respiration, temperature and circulation variables in combination with the patient's subjective experiences of care. Patients may be referred to hospitalization earlier. In the present study investigators will use live continuous and non-continuous biosensor data to monitor the development of vital parameters for Covid 19 patients compared with patients who are not monitored electronically (standard of care).

Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
Two groups, control and intervention.
Masking: None (Open Label)
Masking Description:
Sensor monitoring can not be masked since it is the prerequisite for the measures.
Primary Purpose: Supportive Care
Condition  ICMJE COVID 19
Intervention  ICMJE Device: Biosensors
Sensor that detect vital signs
Other Name: Self reporting status
Study Arms  ICMJE
  • Active Comparator: Control
    Follow general recommendations fram doctor and health authorities what to do and pay attention to before new contact with health service.
    Intervention: Device: Biosensors
  • Active Comparator: Intervention
    Follow general recommendations fram doctor and health authorities what to do and pay attention to before new contact with health service. I addition active reporting of clinical status and continuous vital sign monitoring based on electronic sensors (Welfare technology).
    Intervention: Device: Biosensors
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: April 2, 2020)
214
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE December 20, 2025
Estimated Primary Completion Date April 8, 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Valid informed consent.
  • All Covid 19 positive patients age ≥18 years who are under care at home for Covid 19 infection.
  • Patients with typical Covid 19 clinical symptoms where a test has not been taken may also be included if a test later is positive.
  • Able to log into internet.

Exclusion Criteria:

  • Age <18 years.
  • Covid 19 negative.
  • Internals in prison.
  • Individuals living in special homes due to need of care.
  • Refusal of participation.
  • Comorbidity that hinder the patient to run the system.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Gender Based Eligibility: Yes
Gender Eligibility Description: Ti legally give consent
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE
Contact: Lars Wik, MD 91728966 lars.wik@medisin.uio.no
Listed Location Countries  ICMJE Norway
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04335097
Other Study ID Numbers  ICMJE 127157
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Lars Wik, Ullevaal University Hospital
Study Sponsor  ICMJE Lars Wik
Collaborators  ICMJE
  • University of Stavanger
  • Oslo University Hospital
  • Norwegian Telemedicine
  • University of Basque Country (UPV/EHU)
Investigators  ICMJE
Principal Investigator: Lars Wik, MD Oslo University Hospital
PRS Account Oslo University Hospital
Verification Date May 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP